China Cancer Test Market, 2022 - Market is Expected to Cross US$ 24 Billion
DUBLIN, September 5, 2017 /PRNewswire/ --
The "China Cancer Test Market, Volume, Forecast (By Male & Female), Mortality & 26 Cancer (Oncology) Types Market & Volume to 2022" report has been added to Research and Markets' offering.
By the end of year 2022, China Cancer Test Market is expected to cross US$ 24 Billion
China is the leading consumer of tobacco in the worldwide. Urban and Rural areas face high death rate due to the massive impact of growing cancer diseases in China. In order to alleviate cancer prevalence; the government focuses on several Cancer Control Programs which include prevention, early diagnosis and treatment. Early diagnosis programs include screening for breast and cervix cancer while prevention programs such as anti-smoking campaigns and immunization against hepatitis. Public awareness of cancer and the promotion of healthy lifestyle have also been carried out actively.
In this report, we have studied in-depth analysis of 26 types of cancer in which Lung cancer is leading the market because China has high consumer of tobacco in worldwide. China has an exceptional number of lung cancer diagnoses and deaths than any other part of the world. Cancer is one of the most significant public health burdens in China. The problem will keep moving in near future as China' air pollution goes mostly unchecked.
Lung Cancer leads the China Oncology Market
In China, Lung cancer leads the market in both genders. The report covers the different types of cancers and emphasis on genders. Therefore, the categorization was as follows:
In Male: Lung Cancer is the most predominant cancer and is mainly driven by adult males, half of Chinese men are expected to be current smokers compared to women, followed by Colorectal Cancer, Liver Cancer, Brain, CNS, Esophageal Cancer and Breast Cancer (not in same chorological order).
In Female: Lung cancer cases are less in women as compared to men but other cancers were Liver and Breast Cancer, Uterus and Ovarian Cancer are other most common cancers. Some other Cancers studied in this report are Lip, Oral Cavity, & Pharynx, Nasopharynx, Pancreas, Bone, Prostate, Luekemia, Bladder, Kidney and Lymphoma
Soaring Cancer Mortality Rates
Over the past three decades, Cancer Mortality Rates in China have been rising rapidly. In the urban region, the mortality of cancer is comparatively higher than in rural one. Out of 26 Types of Cancer studied in the report, Lung cancer accounts for the highest fatalities, followed by Digestive Tract Cancers (Stomach, Liver Cancer, Esophageal and Colorectum Cancer).
China Cancer Test Market, Volume, Forecast (By Male & Female), Mortality & 26 Cancer (Oncology) Types Market & Volume to 2022 studies the oncology market in China. This 357 page report with 314 Figures and 12 Tables provides in-depth analysis of China Cancer Tests Market and Volume. All 26 types of cancer in the report have been analyzed from 3 major viewpoints which further study it from 2 different perspectives.
1. China Cancer (Oncology) Screening Tests Market & Forecast
- Male
- Female
2. China Cancer (Oncology) Screening Tests Volume & Forecast
- Male
- Female
3. China Cancer (Oncology) Mortality Rate
All the 26 Cancer Market & Cases Studied in the Report are as Follows:
1. Lip, oral cavity, & pharynx (except nasopharynx)
2. Nasopharynx
3. Esophagus
4. Stomach
5. Colorectum
6. Liver
7. Gallbladder
8. Pancreas
9. Larynx
10. Lung
11. Other thoracic organs
12. Bone
13. Melanoma of the skin
14. Breast
15. Cervix
16. Uterus
17. Ovary
18. Prostate
19. Testis
20. Kidney
21. Bladder
22. Brain, CNS
23. Thyroid
24. Lymphoma
25. Leukemia
26. All other sites and unspecified
For more information about this report visit https://www.researchandmarkets.com/research/67kwlr/china_cancer_test
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article